Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria

J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1389-1390. doi: 10.1016/j.jaip.2018.01.027. Epub 2018 Feb 2.

Authors

Murat Türk¹, Emek Kocatürk², Kübra Cüre², İnsu Yılmaz³

Affiliations

¹ Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey. Electronic address: [email protected].
² Department of Dermatology, Okmeydani Training and Research Hospital, İstanbul, Turkey.
³ Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey.

PMID: 29410306
DOI: 10.1016/j.jaip.2018.01.027

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Anti-Allergic Agents / therapeutic use*
Chronic Disease
Clinical Protocols
Female
Humans
Male
Middle Aged
Omalizumab / therapeutic use*
Urticaria / drug therapy*
Young Adult

Substances

Anti-Allergic Agents
Omalizumab